Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: Are surgical complications or disease related factors responsible?

Urology

Volumn 78, Issue 3, 2011, Pages 595-600

  O'Malley, Rebecca L ^a   Brewer, Katherine A ^a   Hayn, Matthew H ^a   Kim, Hyung L ^a   Underwood III, Willie ^a   Pili, Roberto ^b   Schwaab, Thomas ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; DENDRITIC VACCINE; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VACCINE;

ABDOMINAL ABSCESS; ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CYTOREDUCTIVE NEPHRECTOMY; DISEASE COURSE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; INCISIONAL HERNIA; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METASTATIC RENAL CELL CARCINOMA; MORBIDITY; NEPHRECTOMY; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PLEURA EFFUSION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SMALL INTESTINE OBSTRUCTION; SYSTEMIC THERAPY; THROMBOEMBOLISM; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; WOUND;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; INTRAOPERATIVE COMPLICATIONS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; SURVIVAL RATE;

EID: 80052308057     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.03.009     Document Type: Article

References (23)

1. R. Flanigan, G. Mickisch, and R. Sylvester Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis J Urol 171 2004 1071 1076 (Pubitemid 38327529)
2. N.J. Hellenthal, W. Underwood, and R. Penetrante Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma J Urol 184 2010 859 864
3. A.A. van der Veldt, M.R. Meijerink, and A.J. van den Eertwegh Sunitinib for treatment of advanced renal cell cancer: Primary tumor response Clin Cancer Res 14 2008 2431 2436 (Pubitemid 351551077)
4. S.B. Edge, C.C. Compton The American Joint Committee on Cancer The 7th edition of the AJCC cancer staging manual and the future of TNM Ann Surg Oncol 17 2010 1471 1474
5. R.C. Martin 2nd, M.F. Brennan, and D.P. Jaques Quality of complication reporting in the surgical literature Ann Surg 235 2002 803 813 (Pubitemid 34547298)
6. D. Dindo, N. Demartines, and P.-A. Clavien Classification of Surgical Complications Ann Surg 240 2004 205 213
7. A. Shabsigh, R. Korets, and K. Vora Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology Eur Urol 55 2009 164 176
8. A.S. Levey, L.A. Stevens, and C.H. Schmid A new equation to estimate glomerular filtration rate Ann Intern Med 150 2009 604 612
9. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659 (Pubitemid 33126820)
10. G. Mickisch, A. Garin, and H. Vanpoppel Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970 (Pubitemid 32913522)
11. G. Fyfe, R.I. Fisher, and S.A. Rosenberg Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy JCO 13 1995 688 696
12. S.L. Richey, S.H. Culp, and E. Jonasch Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy Ann Oncol 2010 [Epub November 29]
13. Clinical trial to assess the importance of nephrectomy (CARMENA). http://clinicaltrials.gov/ct2/show/NCT00930033 Accessed January 18, 2011
14. Immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer (EORTC) http://clinicaltrials.gov/ct2/show/ NCT01099423 Accessed January 18, 2011
15. M.L. Fallick, D.F. McDermott, D. LaRock, J.P. Long, and M.B. Atkins Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma J Urol 158 1997 1691 1695 (Pubitemid 27433133)
16. D.A. Levy, D.A. Swanson, J.W. Slaton, J. Ellerhorst, and C.P. Dinney Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma J Urol 159 1998 1168 1173 (Pubitemid 28172786)
17. A. Kutikov, R.G. Uzzo, and A. Caraway Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy BJU Int 106 2009 218 223
18. B. Shuch, J. Said, and J.C. La Rochelle Cytoreductive nephrectomy for kidney cancer with sarcomatoid histologyIs up-front resection indicated and, if not, is it avoidable? J Urol 182 2009 2164 2171
19. W. Kassouf, R. Sanchezortiz, and P. Tamboli Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology J Urol 178 2007 1896 1900 (Pubitemid 47538613)
20. E.J. Abel, S.H. Culp, and S.F. Matin Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: Comparison with nephrectomy assessment J Urol 184 2010 1877 1881
21. V. Margulis, R.F. Sánchez-Ortiz, and P. Tamboli Renal cell carcinoma clinically involving adjacent organs Cancer 109 2007 2025 2030
22. D. You, I.G. Jeong, and J.-H. Ahn The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy J Urol 185 2010 54 59
23. T.K. Choueiri, W. Xie, and C. Kollmannsberger The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy J Urol 185 2010 60 66